Weekly chemotherapy using PMitCEBO in the palliation of recurrent non-Hodgkin's lymphoma.
A chemotherapy schedule comprising mitozantrone, cyclophosphamide, etoposide alternating weekly with bleomycin and vincristine with oral prednisolone throughout (PMitCEBO) has been evaluated in patients relapsing after previous chemotherapy and radiotherapy as a palliative chemotherapy schedule in advanced disease. Treatment was given weekly up to a maximum of 12 weeks, the median duration being 8 weeks (range 2-12 weeks). In 20 patients, median age 70 years (range 52 82), of whom 10 had low-grade NHL and 10 relapsed intermediate/high-grade NHL, the objective response rate was 75% (15/20) with a median duration of response of 12 months (range 1-27 months). Toxicity was restricted to grade 3/4 alopecia and bone marrow depression with three episodes of neutropenic sepsis but no treatment-related deaths.
Hoskin
P J
PJ
Mount Vernon Centre for Cancer Treatment, Mount Vernon Hospital, Northwood, Middlesex, UK. mcrw@mtvern.co.uk
D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D009367:Neoplasm Staging; D010166:Palliative Care; D011239:Prednisolone / Q000008:administration & dosage; D012008:Recurrence; D014750:Vincristine / Q000008:administration & dosage
D001761:Bleomycin; D014750:Vincristine; D005047:Etoposide; D003520:Cyclophosphamide; D011239:Prednisolone; D008942:Mitoxantrone